Dexmedetomidine and Outcomes of Elderly Admitted to ICU After Surgery

September 17, 2023 updated by: Dong-Xin Wang, Peking University First Hospital

Impact of Low-dose Dexmedetomidine on Outcomes of Elderly Admitted to ICU After Noncardiac Surgery: a Randomized Controlled Trial

Sleep disorder and delirium are common problems in intensive care unit (ICU) patients, and may lead to poor prognosis. The investigators' previous study showed that nighttime infusion of low-dose dexmedetomidine improved the sleep quality and decreased the incidence of delirium in ICU patients after surgery. Long-term follow-up of these patients showed that low-dose dexmedetomidine also improved 2-year survival and the quality of life in 3-year survivors. The purpose of this study is to investigate the effect of low-dose dexmedetomidine on the long-term outcome of elderly patients admitted to the ICU after noncardiac surgery.

Study Overview

Detailed Description

Dexmedetomidine is a highly selective α2-adrenoceptor agonist with sedative, analgesic and anti-anxiety properties. Unlike other sedative agents, dexmedetomidine exerts its sedative effects through an endogenous sleep-promoting pathway, producing a state like non-rapid eye movement sleep. For mechanically ventilated patients, sedative-dose dexmedetomidine infusion at night maintains circadian rhythm, increases sleep efficiency, and improves sleep architecture. When used for sedation in mechanical ventilated patients, it reduces the incidence of delirium.

Dexmedetomidine may improve patient outcomes by improving sleep quality. A previous randomized trial found that, for elderly patients who were admitted to ICU after noncardiac surgery, nighttime infusion of low-dose dexmedetomidine significantly improves the sleep quality and decreases the incidence of postoperative delirium. A long-term follow-up of these patients showed that low-dose dexmedetomidine infusion significantly increased survival up to 2 years, and improved cognitive function and quality of life in 3-year survivors.

In the study mentioned above, dexmedetomidine was only infused during the night after surgery with a fixed dose. The investigators hypothesize that, for elderly admitted to ICU after surgery, nighttime infusion of individualized low-dose dexmedetomidine may improve long-term outcomes. This randomized controlled trial is designed to investigate the effect of low-dose dexmedetomidine on 1-year survival and the quality of life of 1-year survivors in elderly patients admitted to the ICU after surgery.

Study Type

Interventional

Enrollment (Estimated)

1410

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Zhao-Ting Meng, MD
  • Phone Number: (86)10-83575138
  • Email: 526589053@qq.com

Study Locations

    • Beijing
      • Beijing, Beijing, China, 100034
        • Recruiting
        • Peking University First Hospital
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age ≥65 years old;
  • Admitted to intensive care unit (ICU) after noncardiac surgery;
  • Expected to stay in ICU until the next morning. For those with endotracheal intubation, the expected duration of mechanical ventilation is <24 hours;
  • Provide written informed consents.

Exclusion Criteria:

  • Preoperative history of schizophrenia, epilepsy, Parkinsonism, or myasthenia gravis;
  • Inability to communicate in the preoperative period (coma, profound dementia, or language barrier);
  • Preoperative history of sleep apnea (previous diagnosis; or STOP-Bang score ≥3 with serum bicarbonate ≥ 28 mmol/L);
  • Known sick sinus syndrome, severe sinus bradycardia (<50 beats per min [bpm]), or second degree or higher atrioventricular block without pacemaker;
  • Hypotension (systolic blood pressure [SBP] <90 mmHg, mean arterial pressure [MAP] <70 mmHg, or a decrease of SBP >30% of baseline) or in a state of shock (vasopressors are required to maintain MAP ≥65 mmHg and serum lactate >2 mmol/L);
  • Severe hepatic dysfunction (Child-Pugh class C), renal failure (requirement of renal replacement therapy), or expected survival <24 hours;
  • Traumatic brain injury or neurosurgery;
  • Presence of delirium before surgery (assessed with Confusion Assessment Method [CAM]/CAM-ICU);
  • Undergoing treatment of dexmedetomidine or clonidine;
  • Other conditions that are considered unsuitable for study participation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Dexmedetomidine group
Dexmedetomidine is infused from 4 pm to 8 am during ICU stay for no more than 3 days.
  1. Dexmedetomidine is infused from 4 pm to 8 am during ICU stay for no more than 3 days.
  2. For non-intubated patients, the infusion rate is adjusted to reach a Richmond Agitation-Sedation Scale (RASS) of -1, or a maximal rate of 0.2 microgram/kg/h, or the occurrence of any adverse events.
  3. For intubated patients, the infusion rate is adjusted to reach a RASS of -1, or a maximal rate of 0.7 microgram/kg/h, or the occurrence of any adverse events.
Placebo Comparator: Placebo group
Normal saline is infused for the same duration as in the dexmedetomidine group.
  1. Normal saline is infused in the same rate for the same duration as in the dexmedetomidine group.
  2. Propofol sedation is administered when considered necessary.
Other Names:
  • Normal saline

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall survival after surgery
Time Frame: Up to 4 years after surgery
Overall survival after surgery
Up to 4 years after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Length of stay in hospital after surgery
Time Frame: Up to 30 days after surgery
Length of stay in hospital after surgery
Up to 30 days after surgery
The incidence of organ injury within 5 days after surgery
Time Frame: Up to 5 days after surgery
Organ injury include delirium (assessed with Confusion Assessment Method/CAM for the Intensive Care Unit), acute kidney injury (assessed with KIDGO criteria), and myocardial injury (assessed with cardiac troponin I).
Up to 5 days after surgery
Length of stay in the intensive care unit (ICU) stay after surgery
Time Frame: Up to 30 days after surgery
Length of ICU stay after surgery
Up to 30 days after surgery
Incidence of postoperative complications within 30 days after surgery
Time Frame: Up to 30 days after surgery
Postoperative complications are defined as newly occured medical events that are harmful to patients' recovery and required interventional therapy.
Up to 30 days after surgery
Rate of all-cause 30-day mortality after surgery
Time Frame: Up to 30 days after surgery
All-cause 30-day mortality after surgery
Up to 30 days after surgery
Sleep quality at 30 days after surgery
Time Frame: At 30 days after surgery
The sleep quality is assessed with the Pittsburgh Sleep Quality Index Questionnaire (PSQI, score ranges from 0 to 21, with higher score indicating poorer sleep quality).
At 30 days after surgery
Recurrence-free survival after surgery
Time Frame: Up to 4 year after surgery
Recurrence-free survival after surgery
Up to 4 year after surgery
Event-free survival after surgery
Time Frame: Up to 4 year after surgery
Event-free survival after surgery
Up to 4 year after surgery
Cancer-specific survival after surgery
Time Frame: Up to 4 year after surgery
Cancer-specific survival after surgery
Up to 4 year after surgery
Quality of life in 1-year survivors after surgery
Time Frame: At the end the 1st year after surgery
The quality of life is assessed with the World Health Organization Quality of Life Questionaire abbreviated version (WHOQOL-BREF, a 24-item questionnaire that provides assessments of the quality of life in physical, psychological, and social relationship, and environmental domains. For each domain, the score ranges from 0 to 100, with higher score indicating better function).
At the end the 1st year after surgery

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain severity within 5 days after surgery: Numeric Rating Scale
Time Frame: Up to 5 days after surgery.
Pain severity is assessed with the Numeric Rating Scale (an 11-point scale where 0=no pain and 10=the worst pain.
Up to 5 days after surgery.
Subjective sleep quality within 5 days after surgery: Numeric Rating Scale
Time Frame: Assessed in the morning on the 1st, 2nd, 3rd, 4th, and 5th day after surgery
Subjective sleep quality the Numeric Rating Scale (an 11-point scale where 0=the best sleep and 10=the worst sleep.
Assessed in the morning on the 1st, 2nd, 3rd, 4th, and 5th day after surgery
Overall survival after surgery in cancer patients
Time Frame: Up to 4 year after surgery
Overall survival after surgery in cancer patients
Up to 4 year after surgery
Recurrence-free survival after surgery in cancer patients
Time Frame: Up to 4 year after surgery
Recurrence-free survival after surgery in cancer patients
Up to 4 year after surgery
Event-free survival after surgery in cancer patients
Time Frame: Up to 4 year after surgery
Event-free survival after surgery in cancer patients
Up to 4 year after surgery
Cancer-specific survival after surgery in cancer patients
Time Frame: Up to 4 year after surgery
Cancer-specific survival after surgery in cancer patients
Up to 4 year after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Dong-Xin Wang, MD, PhD, Peking University First Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 28, 2020

Primary Completion (Estimated)

January 1, 2025

Study Completion (Estimated)

January 1, 2025

Study Registration Dates

First Submitted

December 17, 2019

First Submitted That Met QC Criteria

December 18, 2019

First Posted (Actual)

December 19, 2019

Study Record Updates

Last Update Posted (Actual)

September 21, 2023

Last Update Submitted That Met QC Criteria

September 17, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Surgery

Clinical Trials on Dexmedetomidine

3
Subscribe